WuXi AppTec Co., Ltd. Stock Hong Kong S.E.

Equities

2359

CNE100003F19

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 04:08:06 2024-04-30 am EDT 5-day change 1st Jan Change
35.45 HKD -2.34% Intraday chart for WuXi AppTec Co., Ltd. +3.05% -55.38%

Financials

Sales 2024 * 39.37B 5.44B 42.52B Sales 2025 * 45.15B 6.24B 48.76B Capitalization 126B 17.38B 136B
Net income 2024 * 9.87B 1.36B 10.66B Net income 2025 * 11.4B 1.58B 12.32B EV / Sales 2024 * 2.85 x
Net cash position 2024 * 13.45B 1.86B 14.53B Net cash position 2025 * 16.87B 2.33B 18.22B EV / Sales 2025 * 2.41 x
P/E ratio 2024 *
14 x
P/E ratio 2025 *
11.2 x
Employees 41,116
Yield 2024 *
2.16%
Yield 2025 *
2.42%
Free-Float 66.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.34%
1 week+3.05%
Current month-4.45%
1 month-3.54%
3 months-37.03%
6 months-65.31%
Current year-55.38%
More quotes
1 week
33.35
Extreme 33.35
37.45
1 month
32.60
Extreme 32.6
38.50
Current year
32.60
Extreme 32.6
80.95
1 year
32.60
Extreme 32.6
103.60
3 years
32.60
Extreme 32.6
196.90
5 years
32.60
Extreme 32.6
196.90
10 years
27.61
Extreme 27.6148
196.90
More quotes
Managers TitleAgeSince
Founder 54 00-11-30
Chief Executive Officer 56 00-11-30
Chief Executive Officer 55 15-11-30
Members of the board TitleAgeSince
Chief Investment Officer 61 06-12-31
Director/Board Member 50 16-03-22
Chief Executive Officer 56 00-11-30
More insiders
Date Price Change Volume
24-04-30 35.45 -2.34% 8 990 058
24-04-29 36.3 +3.12% 10,756,350
24-04-26 35.2 +4.30% 9,160,634
24-04-25 33.75 -1.32% 4,825,790
24-04-24 34.2 -0.58% 4,315,674

Delayed Quote Hong Kong S.E., April 30, 2024 at 04:08 am EDT

More quotes
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.; - CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.; - clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.; - other (0.1%). Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
44.57 CNY
Average target price
70.98 CNY
Spread / Average Target
+59.25%
Consensus